{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:44:01Z","timestamp":1788410641042,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tolvaptan, a vasopressin type 2 receptor antagonist, has been used to treat autosomal dominant polycystic kidney disease in Japan since 2014.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This long-term, real-world, post-marketing surveillance (PMS) was conducted in Japan from March 2014 to March 2022. Safety was assessed based on adverse drug reactions (ADRs). For efficacy, changes in the slope of total kidney volume (TKV) and estimated glomerular filtration rate (eGFR) were assessed before and during the administration of tolvaptan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 1676 patients were enrolled, with mean TKV (n\u2009=\u20091000) of 2149\u2009\u00b1\u20091339\u00a0mL and eGFR (n\u2009=\u20091641) of 44.4\u2009\u00b1\u200921.7\u00a0mL\/min\/1.73 m<jats:sup>2<\/jats:sup>. Frequent ADRs were hepatic function abnormal (9.6%), hyperuricaemia (8.3%), and thirst (8.1%). Most of the increased alanine aminotransferase exceeding 3 times the upper limit of the reference level occurred from 3\u2009 to \u200914\u00a0months after the start of treatment, but about 20% was observed after 15\u00a0months. There was no increase in ADRs over 36\u00a0months, suggesting that no other safety concerns need to be monitored during administration over 3\u20137\u00a0years. The mean slope of the estimated TKV increase before and during tolvaptan treatment was 6.58 and 3.71%\/year, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.0020). The mean slope of eGFR decline was \u2212\u00a03.63 and \u2212\u00a03.26\u00a0mL\/min\/1.73 m<jats:sup>2<\/jats:sup>\/year, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.2728).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>There were no major problems with the safety of tolvaptan treatment, and efficacy in limiting TKV increase in this PMS was comparable to the previous, pivotal randomized control trials.<\/jats:p>\n            <jats:p>\n              <jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov; NCT02847624.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10157-025-02634-7","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T18:25:59Z","timestamp":1739557559000},"page":"807-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of tolvaptan in real\u2011world Japanese patients with autosomal dominant polycystic kidney disease: final results of SLOW\u2011PKD surveillance"],"prefix":"10.1007","volume":"29","author":[{"given":"Toshio","family":"Mochizuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Suzue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3296-8139","authenticated-orcid":false,"given":"Satoshi","family":"Komaniwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Fukuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yamashige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"2634_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. The Lancet. 2007;369:1287\u2013301.","journal-title":"The Lancet"},{"key":"2634_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/ki.2009.128","volume":"76","author":"VE Torres","year":"2009","unstructured":"Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76:149\u201368.","journal-title":"Kidney Int"},{"key":"2634_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000045214","volume":"80","author":"E Higashihara","year":"1998","unstructured":"Higashihara E, Nutahara K, Kojima M, et al. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron. 1998;80:421\u20137.","journal-title":"Nephron"},{"key":"2634_CR4","first-page":"1356","volume":"32","author":"CJ Willey","year":"2017","unstructured":"Willey CJ, Blais JD, Hall AK, et al. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2017;32:1356\u201363.","journal-title":"Nephrol Dial Transplant"},{"key":"2634_CR5","first-page":"303","volume":"90","author":"A Srivastava","year":"2014","unstructured":"Srivastava A, Patel N. Autosomal dominant polycystic kidney disease. Am Fam Physician. 2014;90:303\u20137.","journal-title":"Am Fam Physician"},{"key":"2634_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000449394","volume":"2","author":"C Sommerer","year":"2016","unstructured":"Sommerer C, Zeier M. Clinical manifestation and management of ADPKD in Western countries. Kidney Dis. 2016;2:120\u20137.","journal-title":"Kidney Dis"},{"key":"2634_CR7","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/ki.1997.276","volume":"51","author":"RD Perrone","year":"1997","unstructured":"Perrone RD. Extrarenal manifestations of ADPKD. Kidney Int. 1997;51:2022\u201336.","journal-title":"Kidney Int"},{"key":"2634_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i679","volume":"352","author":"RJ Simms","year":"2016","unstructured":"Simms RJ. Autosomal dominant polycystic kidney disease. BMJ. 2016;352: i679.","journal-title":"BMJ"},{"key":"2634_CR9","doi-asserted-by":"publisher","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","volume":"301","author":"GA Reif","year":"2011","unstructured":"Reif GA, Yamaguchi T, Nivens E, et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol. 2011;301:F1005\u201313.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2634_CR10","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Eng J Med. 2012;367:2407\u201318.","journal-title":"N Eng J Med"},{"key":"2634_CR11","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342.","journal-title":"N Engl J Med"},{"key":"2634_CR12","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s10157-021-02097-6","volume":"25","author":"S Nishio","year":"2021","unstructured":"Nishio S, Tsuchiya K, Nakatani S, et al. A digest from evidence-based clinical practice guideline for polycystic kidney disease 2020. Clin Exp Nephrol. 2021;25:1292\u2013302.","journal-title":"Clin Exp Nephrol"},{"key":"2634_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10157-021-02100-0","volume":"25","author":"T Mochizuki","year":"2021","unstructured":"Mochizuki T, Muto S, Miyake M, et al. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance. Clin Exp Nephrol. 2021;25:1231\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"2634_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10157-015-1219-7","volume":"20","author":"S Horie","year":"2016","unstructured":"Horie S, Mochizuki T, Muto S, et al. Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin Exp Nephrol. 2016;20:493\u2013509.","journal-title":"Clin Exp Nephrol"},{"key":"2634_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ki.2013.444","volume":"85","author":"A Levin","year":"2014","unstructured":"Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85:49\u201361.","journal-title":"Kidney Int"},{"key":"2634_CR16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/ki.2013.285","volume":"84","author":"WE Boertien","year":"2013","unstructured":"Boertien WE, Meijer E, de Jong PE, et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int. 2013;84:1278\u201386.","journal-title":"Kidney Int"},{"key":"2634_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.0000000000000022","volume":"18","author":"D Mekahli","year":"2023","unstructured":"Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, et al. Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: randomized controlled trial. Clin J Am Soc Nephrol. 2023;18:36\u201346.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2634_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38:1103\u201313.","journal-title":"Drug Saf"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02634-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02634-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02634-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:19:49Z","timestamp":1748582389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02634-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2634"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02634-7","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Toshio Mochizuki belongs to an endowed department sponsored by Otsuka Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., MSD K.K., and JMS Co., Ltd. Satoru Muto belongs to an endowed department sponsored by Otsuka Pharmaceutical Co. Ltd. Kyoko Suzue, Satoshi Komaniwa, Toshiki Tanaka, Yasuhiko Fukuta, Yuko Yamashige are employees of Otsuka Pharmaceutical\u00a0Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is being conducted in compliance with the Ministerial Ordinance on Standards for Conducting Post-marketing Surveys and Studies on Drugs; MHLW Ordinance No. 171 issued on December 20, 2004. As the study is non-interventional in accordance with GPSP, informed consent from patients and approval of ethical committees in healthcare institutions were not mandatory.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}}]}}